<?xml version='1.0' encoding='utf-8'?>
<document id="10709160"><sentence text="Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment."><entity charOffset="28-40" id="DDI-PubMed.10709160.s1.e0" text="lansoprazole" /><entity charOffset="45-56" id="DDI-PubMed.10709160.s1.e1" text="propranolol" /><pair ddi="false" e1="DDI-PubMed.10709160.s1.e0" e2="DDI-PubMed.10709160.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s1.e0" e2="DDI-PubMed.10709160.s1.e1" /></sentence><sentence text="Due to the prevalence of both gastrointestinal and cardiovascular diseases, it is likely that patients may be coprescribed gastric parietal cell proton pump inhibitors and beta-adrenergic antagonists" /><sentence text=" Therefore, the objectives of this phase I study were to assess the potential effects of the coadministration of lansoprazole on the pharmacokinetics of propranolol and to evaluate the safety of propranolol with concomitant lansoprazole dosing"><entity charOffset="113-125" id="DDI-PubMed.10709160.s3.e0" text="lansoprazole" /><entity charOffset="153-164" id="DDI-PubMed.10709160.s3.e1" text="propranolol" /><entity charOffset="195-206" id="DDI-PubMed.10709160.s3.e2" text="propranolol" /><entity charOffset="224-236" id="DDI-PubMed.10709160.s3.e3" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e0" e2="DDI-PubMed.10709160.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e0" e2="DDI-PubMed.10709160.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e0" e2="DDI-PubMed.10709160.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e0" e2="DDI-PubMed.10709160.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e1" e2="DDI-PubMed.10709160.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e1" e2="DDI-PubMed.10709160.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e1" e2="DDI-PubMed.10709160.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e2" e2="DDI-PubMed.10709160.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10709160.s3.e2" e2="DDI-PubMed.10709160.s3.e3" /></sentence><sentence text=" In a double-blind fashion, 18 healthy male nonsmokers were initially randomized to receive either 60 mg oral lansoprazole, each morning for 7 days, or an identical placebo (period 1)"><entity charOffset="110-122" id="DDI-PubMed.10709160.s4.e0" text="lansoprazole" /></sentence><sentence text=" On day 7, all subjects were concomitantly administered oral propranolol, 80 mg"><entity charOffset="61-72" id="DDI-PubMed.10709160.s5.e0" text="propranolol" /></sentence><sentence text=" After a minimum of 1 week following the last dose of either lansoprazole or placebo, subjects were crossed over to the opposite treatment for another 7 days (period 2)"><entity charOffset="61-73" id="DDI-PubMed.10709160.s6.e0" text="lansoprazole" /></sentence><sentence text=" Subjects were again administered oral propranolol on day 7"><entity charOffset="39-50" id="DDI-PubMed.10709160.s7.e0" text="propranolol" /></sentence><sentence text=" During both treatment periods, blood samples for the determination of plasma propranolol and 4-hydroxy-propranolol were obtained just before the dose and at 0"><entity charOffset="78-89" id="DDI-PubMed.10709160.s8.e0" text="propranolol" /><entity charOffset="94-115" id="DDI-PubMed.10709160.s8.e1" text="4-hydroxy-propranolol" /><pair ddi="false" e1="DDI-PubMed.10709160.s8.e0" e2="DDI-PubMed.10709160.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s8.e0" e2="DDI-PubMed.10709160.s8.e1" /></sentence><sentence text="5, 1, 2, 3, 4, 6, 8 12, 16, 20, and 24 hours postdose" /><sentence text=" Plasma propranolol and 4-hydroxy-propranolol concentrations were determined by using HPLC with fluorescence detection"><entity charOffset="8-19" id="DDI-PubMed.10709160.s10.e0" text="propranolol" /><entity charOffset="24-45" id="DDI-PubMed.10709160.s10.e1" text="4-hydroxy-propranolol" /><pair ddi="false" e1="DDI-PubMed.10709160.s10.e0" e2="DDI-PubMed.10709160.s10.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s10.e0" e2="DDI-PubMed.10709160.s10.e1" /></sentence><sentence text=" The Cmax, tmax, AUC0-infinity, and t1/2 values for propranolol, as well as the AUC0-infinity for 4-hydroxy-propranolol, were calculated and compared between the lansoprazole and placebo regimens"><entity charOffset="52-63" id="DDI-PubMed.10709160.s11.e0" text="propranolol" /><entity charOffset="98-119" id="DDI-PubMed.10709160.s11.e1" text="4-hydroxy-propranolol" /><entity charOffset="162-174" id="DDI-PubMed.10709160.s11.e2" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.10709160.s11.e0" e2="DDI-PubMed.10709160.s11.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s11.e0" e2="DDI-PubMed.10709160.s11.e1" /><pair ddi="false" e1="DDI-PubMed.10709160.s11.e0" e2="DDI-PubMed.10709160.s11.e2" /><pair ddi="false" e1="DDI-PubMed.10709160.s11.e1" e2="DDI-PubMed.10709160.s11.e1" /><pair ddi="false" e1="DDI-PubMed.10709160.s11.e1" e2="DDI-PubMed.10709160.s11.e2" /></sentence><sentence text=" The mean age of the 15 subjects who successfully completed the study was 31 years (range: 24-38 years), and their average weight was 174" /><sentence text="8 pounds (range: 145-203 pounds)" /><sentence text=" There were no statistically significant differences between the lansoprazole and placebo regimens for the propranolol Cmax, tmax, AUC0-infinity, and t1/2 values"><entity charOffset="65-77" id="DDI-PubMed.10709160.s14.e0" text="lansoprazole" /><entity charOffset="107-118" id="DDI-PubMed.10709160.s14.e1" text="propranolol" /><pair ddi="false" e1="DDI-PubMed.10709160.s14.e0" e2="DDI-PubMed.10709160.s14.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s14.e0" e2="DDI-PubMed.10709160.s14.e1" /></sentence><sentence text=" Also, there were no statistically significant differences between regimens for the 4-OH-propranolol AUC0-infinity"><entity charOffset="84-100" id="DDI-PubMed.10709160.s15.e0" text="4-OH-propranolol" /></sentence><sentence text=" Safety evaluations, which included adverse events, vital signs, clinical laboratory determinations, ECG, and physical examinations, revealed no unexpected clinically significant findings and did not suggest a drug-drug interaction" /><sentence text=" In conclusion, lansoprazole does not significantly alter the pharmacokinetics of propranolol, suggesting that it does not interact with the CYP2D6- or CYP2C19-mediated metabolism of propranolol"><entity charOffset="16-28" id="DDI-PubMed.10709160.s17.e0" text="lansoprazole" /><entity charOffset="82-93" id="DDI-PubMed.10709160.s17.e1" text="propranolol" /><entity charOffset="183-194" id="DDI-PubMed.10709160.s17.e2" text="propranolol" /><pair ddi="false" e1="DDI-PubMed.10709160.s17.e0" e2="DDI-PubMed.10709160.s17.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s17.e0" e2="DDI-PubMed.10709160.s17.e1" /><pair ddi="false" e1="DDI-PubMed.10709160.s17.e0" e2="DDI-PubMed.10709160.s17.e2" /><pair ddi="false" e1="DDI-PubMed.10709160.s17.e1" e2="DDI-PubMed.10709160.s17.e1" /><pair ddi="false" e1="DDI-PubMed.10709160.s17.e1" e2="DDI-PubMed.10709160.s17.e2" /></sentence><sentence text=" Modification of a propranolol dosage regimen in the presence of lansoprazole is not indicated, based on the pharmacokinetic analysis and the lack of a clinically significant alteration in the pharmacodynamic response"><entity charOffset="19-30" id="DDI-PubMed.10709160.s18.e0" text="propranolol" /><entity charOffset="65-77" id="DDI-PubMed.10709160.s18.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.10709160.s18.e0" e2="DDI-PubMed.10709160.s18.e0" /><pair ddi="false" e1="DDI-PubMed.10709160.s18.e0" e2="DDI-PubMed.10709160.s18.e1" /></sentence><sentence text="" /></document>